GENOMIC HEALTH,INC. (NASDAQ:GHDX) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

GENOMIC HEALTH,INC. (NASDAQ:GHDX) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

This amended Current Report on Form8-K/A amends Item 2.02 of the Current Report on Form8-K filed by Genomic Health,Inc. (the “Company”) with the Securities and Exchange Commission on March8, 2018, relating to a press release announcing the Company’s financial results for its fourth fiscal quarter and year ended December31, 2017. The financial table in the “2018 Financial Outlook” section describing the Company’s 2018 financial guidance has been updated to correct the calculation for GAAP and non-GAAP earnings per share as well as to revise the exclusion criteria for non-GAAP net income. The full text of the amended press release is furnished as Exhibit99.1.


GENOMIC HEALTH INC Exhibit
EX-99.1 2 a18-7924_1ex99d1.htm EX-99.1 Exhibit 99.1     Contacts: Investors: Emily Faucette Genomic Health 650-569-2824 [email protected]   Media: Victoria Steiner Genomic Health 415-370-5804 [email protected]   Genomic Health Announces 2017 Fourth Quarter and Year-end Financial Results,…
To view the full exhibit click here

About GENOMIC HEALTH,INC. (NASDAQ:GHDX)

Genomic Health, Inc. is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer. Its Oncotype DX tests utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction, in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. It offers its services and products, including Oncotype DX Breast Cancer Test, Oncotype DX Colon Cancer Test and Oncotype DX Prostate Cancer Test through its Oncotype IQ Genomic Intelligence Platform.